var data={"title":"Meningococcal group B vaccine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Meningococcal group B vaccine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/706310?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=meningococcal-group-b-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Meningococcal group B vaccine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=meningococcal-group-b-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Meningococcal group B vaccine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26524936\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bexsero;</li>\n      <li>Trumenba</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24034439\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bexsero;</li>\n      <li>Trumenba</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22783466\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22907273\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal group B disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling (Bexsero): </i>Adults &le;25 years: IM: 0.5 mL/dose given as a 2-dose series at least 1 month apart</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling (Trumenba): </i> Adults &le;25 years: <b>Note:</b> Consider risk of exposure and patient&rsquo;s susceptibility to the disease when choosing a schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2-dose schedule: IM: 0.5 mL per dose given as a 2-dose series according to a 0- and 6-month schedule. <b>Note:</b> If the interval between the first and second dose is &le;6 months, administer a third dose &ge;4 months after the second dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3-dose schedule: IM: 0.5 mL per dose given as a 3-dose series at 0-, 1- to 2-, and 6-months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ACIP recommendations for Trumenba (ACIP [Patton 2017]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients at increased risk for serogroup B meningococcal disease and during serogroup B meningococcal disease outbreak</i>: Administer 3-dose series at 0, 1 to 2 months, and 6 months. If the interval between the first and second dose is &ge;6 months, then the third dose is not needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients 16 to 23 years of age who are not at increased risk for meningococcal disease:</i> Administer a 2-dose series at 0 and 6 months. If the interval between the first and second dose is &le;6 months, then a third dose &ge;4 months later should be administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24034478\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=meningococcal-group-b-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Meningococcal group B vaccine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal group B disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling (Bexsero): </i>Children &ge;10 years and Adolescents: IM: 0.5 mL/dose given as a 2-dose series at least 1 month apart</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling (Trumenba):</i> Children &ge; 10 years and Adolescents: <b>Note:</b> Consider risk of exposure and patient&rsquo;s susceptibility to the disease when choosing a schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2-dose schedule: IM: 0.5 mL per dose given as a 2-dose series according to a 0- and 6-month schedule. <b>Note:</b> If the interval between the first and second dose is &le;6 months, administer a third dose &ge;4 months after the second dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">3-dose schedule: IM: 0.5 mL per dose given as a 3-dose series according to a 0-, 1- to 2-, and 6-month schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>ACIP recommendations for Trumenba</i> (ACIP [Patton 2017]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Children and adolescents &ge;10 years of age</i>\n      <i> at increased risk for serogroup B meningococcal disease and during serogroup B meningococcal disease outbreak</i>: Administer 3-dose series at 0, 1 to 2 months, and 6 months. If the interval between the first and second dose is &ge;6 months, then the third dose is not needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adolescents &ge;16 years of age who are not at increased risk for meningococcal disease:</i> Administer a 2-dose series at 0 and 6 months. If the interval between the first and second dose is &le;6 months, then a third dose &ge;4 months later should be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling (Bexsero):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 2 to 5 months: IM: Total of 4 doses (0.5 mL each); a primary infant series is administered at 2, 4, and 6 months of age followed by a booster dose between 12 to 23 months of age; alternatively, may give first 3 doses at 2, 3, and 4 months of age, however, the immune response to 1 component (NHBA) of the vaccine is reduced with this regimen</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants 6 months to &lt;12 months (unvaccinated): IM: Total of 3 doses (0.5 mL each) with first and second dose administered at least 2 months apart; third dose is administered during second year of life at least 2 months after the second dose. The necessity of a booster dose has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;1 year to &lt;2 years (unvaccinated): IM: Total of 2 doses (0.5 mL each) administered at least 2 months apart. The necessity of a booster dose has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years to &lt;11 years: IM: Total of 2 doses (0.5 mL each) administered at least 2 months apart. The necessity for subsequent dosing has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;11 years to Adolescents &le;17 years: IM: Total of 2 doses (0.5 mL each) administered at least 1 month apart. The necessity for subsequent dosing has not been determined.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26524995\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26524996\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26536174\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Prefilled Syringe, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bexsero:  (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trumenba:  (0.5 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26524938\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24034481\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, Suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bexsero: <i>Neisseria meningitidis</i> serogroup B protein antigens NHBA 50 mcg, NadA 50 mcg, fHbp 50 mcg, and OMV PorA P1.4 25 mcg per 0.5 mL dose (0.5 mL) [packaging contains latex; prefilled syringe]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46549865\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;\">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening-serogroup.html&amp;token=aK/CcoQdX/5TmLpK2VFkC7EF6ocC7JFwObz3NLDuW53jqgBEPnlr+wol1zqTkUGfeBnplVkDAn9lTLNxrcRzY4762AEsipb4jEWBt+XgIU8=&amp;TOPIC_ID=91590\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mening-serogroup.html</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24034479\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: For IM administration only, preferably into the anterolateral aspect of the thigh in infants (Bexsero [Canadian product]) and in the upper deltoid region in children, adolescents, or adults (Bexsero or Trumenba). Do not administer via IV, SubQ, or intradermal route. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage, the vaccine should be administered IM if, in the opinion of a health care provider familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, IM vaccination can be scheduled shortly after such therapy is administered. A fine needle (23-gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient or family should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24034440\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Meningococcal disease prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Active immunization of children, adolescents, and adults aged 10 to 25 years against invasive meningococcal disease caused by <i>N. meningitidis</i> serogroup B.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of certain groups of persons &ge;10 years of age (ACIP [Folaranmi 2015]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons with persistent complement component deficiencies (including patients who are taking eculizumab [Solaris])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons with anatomic or functional asplenia (including sickle cell disease)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Microbiologists routinely exposed to isolates of <i>Neisseria meningitidis</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Persons identified to be at increased risk due to a serogroup B meningococcal disease outbreak</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The ACIP states that a meningococcal group B vaccination series may be administered to adolescents and young adults aged 16 to 23 years to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for vaccination is 16 to 18 years (ACIP [MacNeil 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: Additional ages (not in US labeling):</i> Bexsero: Indicated for infants &ge;2 months, children, and adolescents through 17 years</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24526119\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequencies reported may include concomitant administration with routine pediatric vaccines or other vaccines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Irritability (infants and children: 43% to 79%), drowsiness (infants and children: 53% to 72%; children: 30% to 51%), excessive crying (infants and children: 56% to 69%; children: 27% to 33%), fatigue (children, adolescents, and adults: 35% to 62%), headache (10% to 55%), malaise (children and adolescents: 50% to 56%; adults: 14%), chills (children and adolescents: 16% to 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Change in appetite (infants and children: 21% to 51%), diarrhea (children: 2% to 37%; infants and children: 18% to 24%; children and adolescents: years 9% to 15%), nausea (children, adolescents, and adults: 16% to 19%), vomiting (infants, children, and adolescents: &le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (children, adolescents, and adults: 82% to 98%), erythema at injection site (children: 60% to 98%; infants and children: 60% to 64%; children, adolescents, and adults: 45% to 54%), tenderness at injection site (children: 81% to 89%; infants and children: 65% to 66%), swelling at injection site (children: 26% to 63%; children and adolescents: 18% to 39%; infants and children: 26% to 31%), induration at injection site (infants and children: 33% to 56%; children, adolescents, and adults: 28% to 40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (children, adolescents, and adults: 31% to 57%), arthralgia (children, adolescents, and adults: 13% to 33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (infants and children: 69% to 79%, &ge;40&deg;C [104&deg;F] &le;1%; children: 10% to 28%, &ge;40&deg;C [104&deg;F] &le;3%; children, adolescents, and adults: 1% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (children: &le;9%), urticaria (infants and children: 5% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (infants: 10%; mostly considered unrelated to vaccination), nasopharyngitis (children, adolescents, and adults: &ge;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% (postmarketing, and/or case reports): Eczema, febrile seizures, hypersensitivity reaction (includes anaphylaxis), injection site blister formation, injection site nodule, Kawasaki syndrome, pallor, seizure, swelling of eye, syncope, vasodepressor syncope</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22783352\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypersensitivity to the meningococcal group B vaccine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Trumenba: Severe allergic reactions (eg, anaphylaxis) after a previous dose of this vaccine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22906405\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concerns related to adverse effects:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Apnea: Post immunization apnea may occur in premature infants, particularly if history of respiratory immaturity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Disease-related concerns:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meningococcal infections: Not to be used to treat meningococcal infections or to provide immunity against <i>N. meningitidis</i> serogroups A, C, W-135, or Y. In addition, vaccine does not provide protection against all circulating meningococcal group B strains.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Concurrent drug therapy issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. Because of differences in components and dosing regimen, meningococcal group B vaccines are not interchangeable (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Special populations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage form specific issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kanamycin: May contain kanamycin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The packaging (needle cover of prefilled syringe) may contain latex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other warnings/precautions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends on multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22813132\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22813129\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=91590&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eculizumab: May diminish the therapeutic effect of Meningococcal Group B Vaccine. Meningococcal Group B Vaccine may diminish the therapeutic effect of Eculizumab. The meningococcal vaccine may result in increased complement activation, possibly worsening the symptoms of any underlying complement-mediated diseases, such as hemolysis and anemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26524940\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (manufacturer specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22906403\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were not observed in animal reproduction studies. Inactivated vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]). However, the ACIP recommends deferring meningococcal group B vaccination in pregnant women unless the woman is at increased risk for meningococcal disease and vaccination benefits outweigh the potential risks (ACIP [Patton 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to Bexsero during pregnancy in the Bexsero Pregnancy Registry (1-877- 413-4759); women may also enroll themselves.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22906404\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this vaccine is excreted into breast milk. The manufacturer recommends that caution be used if administered to breastfeeding women. The ACIP recommends deferring meningococcal group B vaccination in breastfeeding women unless the woman is at increased risk for meningococcal disease and vaccination benefits outweigh the potential risks (ACIP [Patton 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24034480\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory function for 48 to 72 hours following vaccination in premature infants (particularly if born &le;28 weeks gestation or if prior history of respiratory immaturity). Monitor for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22907033\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bexsero: Induces immunity against meningococcal disease caused by serogroup B <i>Neisseria meningitidis</i> (MenB) via the formation of antibodies directed toward the recombinant protein antigens combined together with outer membrane vesicles (OMV) from a group B strain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trumenba: Protection against invasive meningococcal disease is conferred mainly by complement-mediated antibody-dependent killing of <i>N. meningitidis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efficacy:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bexsero: Composite hSBA titer response one month after the second dose: 63% to 88%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trumenba: 84% of adolescents had a &ge;4-fold rise in hSBA titer and composite response after the third dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23671423\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bexsero (AT, AU, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, LT, LV, MT, NL, NO, PL, PT, SE, SK);</li>\n      <li>Trumenba (AT, AU, CZ, DE, DK, GB, HR, LT, LV, NL, NO, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bexsero (multicomponent meningococcal B vaccine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bexsero (multicomponent meningococcal B vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Serogroup B Meningococcal Vaccine Questions and Answers. <a href=\"http://www.cdc.gov/meningococcal/vaccine-serogroupB.html#serogroup\" target=\"_blank\">http://www.cdc.gov/meningococcal/vaccine-serogroupB.html#serogroup</a>. Accessed March 7, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Folaranmi T, Rubin L, Martin S, Patel M, MacNeil JR; Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged &ge;10 years at increased risk for serogroup B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(22):608-612.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/26068564/pubmed\" target=\"_blank\" id=\"26068564\">26068564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gossger N, Snape MD, Ly-Mee Y, et al, Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. <i>JAMA</i>. 2012;307(6):573-582.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/22318278/pubmed\" target=\"_blank\" id=\"22318278\">22318278</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, et al; Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017; 66(5):136-138. doi: 10.15585/mmwr.mm6605e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(41):1171-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/26492381/pubmed\" target=\"_blank\" id=\"26492381\">26492381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patton ME, Stephens D, Moore K, MacNeil JR. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine &mdash; Advisory Committee on Immunization Practices, 2016. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66:509&ndash;513. doi: 10.15585/mmwr.mm6619a6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/28520709/pubmed\" target=\"_blank\" id=\"28520709\">28520709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al; Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trumenba (meningococcal group B vaccine) [prescribing information]. Philadelphia, PA; Wyeth; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trumenba (meningococcal group B vaccine) [product monograph]. Kirkland, Quebec, Canada; Pfizer Canada; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. <i>Lancet</i>. 2013;381(9869): 825-835.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/meningococcal-group-b-vaccine-drug-information/abstract-text/23324563/pubmed\" target=\"_blank\" id=\"23324563\">23324563</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 91590 Version 95.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26524936\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F24034439\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F22783466\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F22907273\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F24034478\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F26524995\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26524996\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26536174\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26524938\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F24034481\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F46549865\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24034479\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F24034440\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F24526119\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F22783352\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F22906405\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F22813132\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F22813129\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F26524940\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F22906403\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F22906404\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F24034480\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F22907033\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23671423\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/91590|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=meningococcal-group-b-vaccine-patient-drug-information\" class=\"drug drug_patient\">Meningococcal group B vaccine: Patient drug information</a></li><li><a href=\"topic.htm?path=meningococcal-group-b-vaccine-pediatric-drug-information\" class=\"drug drug_pediatric\">Meningococcal group B vaccine: Pediatric drug information</a></li></ul></div></div>","javascript":null}